Skip to main content
OpenTrials
Completed

NCT Number: NCT00171210

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

A 1-year randomized Phase III core trial (NCT00061750) using deferoxamine as the comparator was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older. Patients who successfully completed this main trial may continue in this extension trial to receive chelation therapy with deferasirox for an additional 4 years.

The objective of this study is to assess the efficacy and long-term safety of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Transfusional Iron Overload in β-thalassemia Iron Metabolism Disorders Iron Overload Metabolic Diseases Nutritional and Metabolic Diseases

Age range

2 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Novartis Investigative Site, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who completed the 12-month core study (NCT00061750)
  • Female patients after menarche and who were sexually active, if they used double-barrier contraception, oral contraceptive plus barrier contraceptive, or had undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation
  • Written informed consent obtained from the patient and/or legal guardian on the patient's behalf in accordance with the national legislation

Exclusion criteria

  • Pregnant or breast feeding patients
  • Patients with a history of non-compliance to medical regimens or those considered to be potentially unreliable

Treatment and study plan

Deferasirox

Drug

Tablets taken orally once a day.

Primary outcomes

  1. Long Term Safety and Tolerability Profile of ICL670 Based on the Number of Participants Who Experienced Any Adverse Event

    Time frame: up to 5 years

    Adverse events results are based on preferred terms with at least 7% of participants in any group.

Secondary outcomes

  1. Long-term Effect of ICL670 on Hepatic Iron Stores Measured by Means of Liver Iron Content (LIC) as Assessed by Liver Biopsy

    Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)

    Mean absolute change of LIC from start of Deferasirox (ICL670) treatment to the end of study assessed by liver biopsy. Reported in milligrams of Iron per gram dry weight (mg Fe/g dw).

  2. Long-term Effect of ICL670 on Hepatic Iron Stores Measured by Means of Liver Iron Content (LIC) as Assessed by SQUID

    Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)

    Mean absolute change in LIC from start of Deferasirox (ICL670) treatment to the end of the study assessed by Superconducting Quantum Interfering Device (SQUID) measurement used as a non-invasive alternative to Biopsy for pediatric participants. Reported in milligrams of Iron per gram dry weight (mg Fe/g dw).

  3. Long-term Effect of Treatment With ICL670 on the Changes in Serum Ferritin Levels From Start of ICL670 Treatment to End of Study

    Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)

    Mean Absolute Change in serum ferritin (ug/L) from start of treatment with Deferasirox (ICL670) to end of study taking into account the therapeutic goal which will either be to maintain iron balance or to induce negative iron balance. End of study taken as the mean of, at most, the last three available results after start of treatment with ICL670.

  4. Change in Surrogate Marker: Serum Transferrin From Start of Treatment With ICL670 to End of Study

    Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)

    Measurement of the relative change in percent of potential surrogate marker: Serum Transferrin (g/L) from start of treatment with Deferasirox (ICL670) to end of study.

    (Serum Transferrin at the End of Study-Serum Transferrin at Start of ICL670)/Serum Transferrin at Start of ICL670*100.

  5. Change in Surrogate Marker: Serum Iron From Start of Treatment With ICL670 to End of Study

    Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)

    Measurement of the relative change of potential surrogate markers: Serum Iron (µmol/L) from start of treatment with Deferasirox (ICL670) to end of study.

    (Serum Iron at the End of Study-Serum Iron at Start of ICL670)/Serum Iron at Start of ICL670*100.

  6. Change in Surrogate Marker: Transferrin Saturation From Start of Treatment With ICL670 to End of Study

    Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)

    Measurement of the relative change of potential surrogate marker: Transferrin Saturation (Percent) from start of treatment with Deferasirox (ICL670) to end of study.

    (Transferrin Saturation at the End of Study-Tranferrin Saturation at Start of ICL670)/Transferrin Saturation at Start of ICL670*100.

  7. Absolute Change in Liver Iron Content From Start of ICL670 Treatment to End of Study Measured by Biopsy

    Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)

    Measurement of median absolute change in liver iron content (LIC) from start of treatment with Deferasirox (ICL670) to end of study obtained through biopsy. Absolute change = End of study value - start of treatment value. LIC is expressed in mg of iron per gram of liver dry weight (mg Fe/g dw).

  8. Relative Change in Liver Iron Content From Start of ICL670 Treatment to End of Study Measured by Biopsy

    Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)

    Relative change in liver iron content (LIC) as measured by biopsy and calculated by: End of study value - Start of ICL670 treatment value (absolute change) / Start of ICL670 treatment value.

  9. Absolute Change in Liver Iron Content From Start of ICL670 Treatment to End of Study Measured by SQUID

    Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)

    Measurement of the median absolute change in liver iron content (LIC) from start of treatment with Deferasirox (ICL670) to end of study obtained through Superconducting Quantum Interfering Device (SQUID). Absolute change = End of study value - start of treatment value. LIC is expressed in mg of iron per gram of liver dry weight (mg Fe/g dw).

  10. Relative Change in Liver Iron Content From Start of ICL670 Treatment to End of Study as Measured by SQUID

    Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)

    Relative change in liver iron content (LIC) measured by Superconducting Quantum Interfering Device (SQUID), calculated by: End of study value - Start of ICL670 treatment value (absolute change) / Start of ICL670 treatment value.

  11. Change of Total Body Iron Excretion Rate (TBIE) From Start of ICL670 Treatment to the End of Study

    Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)

    Median change in TBIE (mg/kg/day) from start of treatment with Deferasirox (ICL670) to end of study.

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670)in β-thalassemia Patients With Transfusional Iron Overload

Important dates

Study start
2004
Primary completion
2008
First posted
Sep 15, 2005
Registry last updated
May 30, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.